Register
Sarecycline approved for moderate to severe acne |
Journal Updates
eMediNexus Coverage from: 
Sarecycline approved for moderate to severe acne
eMediNexus,  03 October 2018
remove_red_eye 604 Views
#Dermatology #Pharmacist

0 Read Comments                

The US Food and Drug Administration (FDA) has approved sarecycline (Seysara, Almirall) for patients aged 9 years and older with inflammatory lesions associated with non-nodular moderate to severe acne vulgaris. It is a new first-in-class tetracycline-derived oral antibiotic and the first one specifically designed for dermatologic use in more than four decades.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!